Physical and Chemical Study of Atherosclerosis Mechanisms

NCT01700075 · Completed

Last updated 2026-05-28

This clinical trial studies how atherosclerosis develops in people with heart disease, diabetes, or artery blockages to better understand the condition.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 97 people

Who can join Ages 26–70 · all sexes Healthy volunteers accepted.

Timeline Started 2009-01 · est. completion 2011-12

Where 1 site · Kazakhstan

What this study is testing ClinicalTrials.gov NCT01700075 ↗

Description as written by the study sponsor.

Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.

Treatments tested

Conventional treatment also known as Pathogenetic and symptomatic treatment Drug

Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day. Antihypertensive: "Diroton" (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and "Ditiazem" (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day. Antihyperglycemic drugs: biguanides "Metformin" - 0.5 g two or tree times per day, or "Exenatide" - 5-10 µg per day. Anti-inflammatory: "TromboACC" (acetylsalicylate acid) up to 2 g per day and/or "Clopidogrel" (thienopyridine class antiplatelet agent) - 75mg per day.
Weight loss treatment also known as vegetable and salt diet Dietary supplement

Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.

Main thing measured	full recovery from atherosclerotic diseases
Sponsor	Nazarbayev University
Conditions studied	Myocardial Infarction, Coronary Artery Diseases, Diabetes Mellitus, Type 2, Atherosclerosis of Femoral Artery
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01700075 ↗